cyclophosphamid beta 2000 mg/4 ml konzentrat zur herstellung einer injektions-/infusionslösung
cyclophosphamid beta 1000 mg/2 ml konzentrat zur herstellung einer injektions-/infusionslösung
endoxan 500 mg injection
megapharm ltd - cyclophosphamide - powder for solution for injection - cyclophosphamide 500 mg/vial - cyclophosphamide - cyclophosphamide - malignant diseases: cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible. cycophosphamide treatment: 1) malignant lymphomas (stages iii and iv of the ann arbor staging system) hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma burkitt`s lymphoma. 2) multiple myeloma. 3) leukemias: chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) mycosis fungoides (advenced disease). 5) neuroblastoma (disseminated disease). 6) adenocarcinoma of the ovary. 7) retinoblastoma. 8) carcinoma of the breast. nonmallgnant disease biopsy proven "minimal change" nephrotic syndrome in children whose disease fails to respond adequately to another treatment. severe cases of systemic lupus erythematos as which did not respond to other treatment especially with nephritis
endoxan 1 g injection
megapharm ltd - cyclophosphamide - powder for solution for injection - cyclophosphamide 1 g/vial - cyclophosphamide - cyclophosphamide - malignant diseases: cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible. cycophosphamide treatment: 1) malignant lymphomas (stages iii and iv of the ann arbor staging system) hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma burkitt`s lymphoma. 2) multiple myeloma. 3) leukemias: chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) mycosis fungoides (advenced disease). 5) neuroblastoma (disseminated disease). 6) adenocarcinoma of the ovary. 7) retinoblastoma. 8) carcinoma of the breast. nonmallgnant disease biopsy proven "minimal change" nephrotic syndrome in children whose disease fails to respond adequately to another treatment. severe cases of systemic lupus erythematos as which did not respond to other treatment especially with nephritis
cyclophosphamide 2g powder for solution for injection vials
sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 2gram
cyclophosphamide 1g powder for solution for injection vials
sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 1gram
cyclophosphamide 500mg powder for solution for injection vials
sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 500mg
cyclophosphamide-asteria powder for solution for injection
hankook korus pharm co. - cyclophosphamide - powder for solution for injection - 500mg
cyclophosphamid beta 500 mg/ml konzentrat zur herstellung einer injektions-/infusionslösung
endoxana
baxter healthcare limited - cyclophosphamide monohydrate - coated tablets - 50 milligram - cyclophosphamide